Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872289 | 0.88 | JAK2 (0.40) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL21201787 | 0.87 | JAK2 (0.37) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL26541045 | 0.83 | JAK2 (0.42) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL10247499 | 0.81 | JAK2 (0.38) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL18745052 | 0.80 | JAK2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22826701 | 0.80 | JAK2 (0.36) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL18638787 | 0.79 | TPH1 (0.32) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL18638470 | 0.79 | TPH1 (0.32) | SIGMAR1 | |
| SCHEMBL30749812 | 0.79 | JAK2 (0.37) | JAK2JAK1TYK2JAK3SIGMAR1 | |
| SCHEMBL2605520 | 0.79 | JAK2 (0.37) | JAK2JAK1TYK2JAK3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3771716-A1 | LOW HYGROSCOPIC AMORPHOUS FORM OF BARICITINIB | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2021-02-03 | — | — | EP | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 11/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.